| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.0093 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.0019 | 0.9 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.0018 | 0.9 |